Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DE-104 in Glaucoma and Ocular Hypertension
NCT00868894Phase 2Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Mar 2009
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DE-104 in primary open-angle glaucoma (POAG), ocular hypertension, sponsored by Santen Pharmaceutical. Started Mar 2009; status: completed.
02
Drugs
DE-104
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT00868894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00868894.